Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;6(1):1-9.
doi: 10.1007/s40801-018-0146-9.

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review

Reeti Joshi  1 , Dominick Latremouille-Viau  2 , Mark K Meiselbach  3 , Jipan Xie  4 , Yujin Park  5 , Prashanth Sunkureddi  6
Affiliations

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review

Reeti Joshi et al. Drugs Real World Outcomes. 2019 Mar.

Abstract

Objectives: To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.

Methods: This descriptive analysis of data from a US retrospective medical chart review included patients aged ≥ 18 years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Information on physician-level characteristics and reasons for secukinumab prescription and dosing were also collected.

Results: Medical charts from 78 patients with AS who initiated secukinumab were reviewed by 25 rheumatologists between 7 July 2017 and 11 August 2017. Overall, 76.9% of patients were male, mean (SD) age was 39.8 (10.8) years, and 34.6% were biologic naïve. The most common reasons for secukinumab initiation among biologic-naïve and biologic-experienced patients, respectively, were efficacy/effectiveness (77.8%) and failure of other prior biologics (84.3%). Nearly all patients (94.9%) received a loading dose, including 150 mg every week (39.7%), 300 mg every week (53.8%), and other (1.3%). Overall, 73 patients (93.6%) received ≥ 1 maintenance secukinumab dose, of whom 56.2% and 43.8% received 150 mg and 300 mg, respectively, every 4 weeks.

Conclusions: In this US medical chart review of patients with AS who initiated secukinumab, approximately one-third were biologic naïve, and secukinumab efficacy/effectiveness and failure of other biologics were the most common reasons for initiating secukinumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

R. Joshi has received consulting fees from Novartis. D. Latremouille-Viau, M. K. Meiselbach, and J. Xie are employees of Analysis Group, Inc. Y. Park is an employee of Novartis Pharmaceuticals Corporation. P. Sunkureddi has received consulting and speakers’ bureau fees from Novartis, and is an investigator of a clinical trial sponsored by Novartis.

Research involving human participants

An institutional review board exemption was obtained for the study prior to initiation of data collection.

Informed consent

Informed consent was not required in this study because the data collected did not contain personal identifiers.

Figures

Fig. 1
Fig. 1
a Rheumatologist-reported reasons for discontinuing the treatment that directly preceded secukinumab initiation in patients with AS and b rheumatologist-reported reasons for secukinumab prescription in patients with AS (N = 78). AS ankylosing spondylitis
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563–2574. doi: 10.1056/NEJMra1406182. - DOI - PubMed
    1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–1390. doi: 10.1016/S0140-6736(07)60635-7. - DOI - PubMed
    1. Reveille JD. Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011;341:284–286. doi: 10.1097/MAJ.0b013e31820f8c99. - DOI - PMC - PubMed
    1. Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905–910. doi: 10.1002/acr.21621. - DOI - PMC - PubMed
    1. Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci. 2013;345:431–436. doi: 10.1097/MAJ.0b013e318294457f. - DOI - PMC - PubMed